Bavarian Nordic Announces Promising Mpox Vaccine Results in Children
Bavarian Nordic,a Danish biotechnology company,reported positive results from a clinical study evaluating its MVA-BN vaccine against Mpox (formerly known as monkeypox) in children aged 2 to 11 years.Teh findings, released in a company press release, demonstrate a robust immune response in young recipients.
The study involved 460 children in the Democratic Republic of Congo and Uganda. Researchers found that the children’s immune response to the vaccine was at least comparable to that observed in adults two weeks after the second dose. Importantly, the vaccine’s safety profile and ability to trigger an immune response mirrored previous data from adult trials.
Notably, the immune response in children, as measured by neutralizing antibody titers, was 2.5 times greater than that seen in adults. The vaccine proved well-tolerated, with no unexpected adverse events reported during the trial.
Bavarian Nordic intends to submit these data to the European Medicines Agency (EMA) in 2026. The company seeks to broaden the vaccine’s approval to include children aged two years and older, expanding protection against Mpox to a wider population.
The company did not disclose any financial details related to the study or vaccine production.
Mpox, a viral disease related to smallpox, gained global attention in 2022 with outbreaks reported in multiple countries.Vaccination remains a crucial public health strategy to control the spread of the virus. The development of effective vaccines for pediatric populations is particularly important for long-term disease management and prevention.
Frequently Asked Questions about the Bavarian Nordic Mpox Vaccine
What is the MVA-BN vaccine?
MVA-BN is a vaccine developed by Bavarian Nordic designed to protect against both Mpox and smallpox. it utilizes a modified vaccinia Ankara (MVA) vector.
How effective is the Mpox vaccine in children?
The recent study shows the vaccine elicits a strong immune response in children aged 2-11, with antibody levels 2.5 times higher than those observed in adults.
Was the Mpox vaccine safe for children in the study?
Yes, the vaccine was well-tolerated by the children participating in the study, and no unexpected side effects were reported.
When will the Mpox vaccine be available for children in Europe?
Bavarian Nordic plans to submit data to the European Medicines Agency in 2026, with the goal of expanding vaccine approval to include children aged two and over.
Where was the Mpox vaccine study conducted?
The clinical study took place in the Democratic Republic of Congo and Uganda, involving 460 children.
I hope you found this article informative! If you have any thoughts or questions, please share them in the comments below. Don’t forget to subscribe to world-today-news.com for the latest updates on global health and biotechnology.
